首页 | 本学科首页   官方微博 | 高级检索  
     

益智丹治疗儿童多动症的临床与实验研究
引用本文:陈永辉,黄斌,赵霞. 益智丹治疗儿童多动症的临床与实验研究[J]. 中国中西医结合杂志, 2001, 21(1): 19-21
作者姓名:陈永辉  黄斌  赵霞
作者单位:1. 河南中医学院 郑州 450003
2. 郑州市管城中医院
3. 南京中医药大学
摘    要:内容提要 目的:观察益智丹治疗儿童多动症(CHS)的临床疗效及其作用机制。方法:临床研究采用单盲法随机观察益智丹与利他林的临床疗效;实验研究制作记忆障碍模型,观察举智丹对小鼠学习记忆功能和对小鼠脑组织单受类神经递质含量的影响。结果:益智丹治疗CHS的显效率,总有效率分别为45.56%,87.78%,与利他林(53.33%,86.67%)相当,Conners指数均明显降低,两组间疗效及多动指数比较差异均无显著性(P>0.05),益智丹还能显著改善患儿软神经征及异常脑电图,副反应低于利他林组(P<0.01),对东莨菪碱,亚硝酸钠,乙醇致致的小鼠学习 明显的改善作用(P<0.05),且能够显著提高小鼠脑组织多巴胺(DA)含量,与对照组比较差异有显著性(P<0.01);对二羟苯乙酯(DOPAC),去甲肾上腺素(NE),3-甲氧-4-羟基苯乙酸(HVA),5-羟色胺(5-HT),5-羟吲哚乙酸(5-HIAA)也有不同程度的影响。结论:益智丹是治疗CHS的有效药物,其作用机制可能与改善记忆,提高脑组织DA含量有关。

关 键 词:儿童多动症  益智丹  利他林  中西医结合治疗
修稿时间:2000-06-06

Clinical and Experimental Study on Treatment of Childhood Hyperkinetic Syndrome with Yizhidan
CHEN Yong-hui,CHEN Yong-hu and HUANG Bin. Clinical and Experimental Study on Treatment of Childhood Hyperkinetic Syndrome with Yizhidan[J]. Chinese journal of integrated traditional and Western medicine, 2001, 21(1): 19-21
Authors:CHEN Yong-hui  CHEN Yong-hu  HUANG Bin
Abstract:To observe the clinical effect of Yizhidan (YZD) in treating childhood hyperkinetic syndrome (CHS) and its mechanism. Methods: Random single blind method was used in clinical study to observe the clinical effect of YZD and compared with that of Ritalin. The dysmnesia model animal was used to observe the effect of YZD on learning memory function and cerebral monoamine neurotransmitter content. Results: The markedly effective rate and the total effective rate of YZD were 45.56% and 87.78%, which were similar to those of Ritalin (53.33% and 86.67%). The Conners index lowered in both groups, showing insignificant difference (P>0 05). Experimental observation showed that YZD could significantly improve the soft neurologic signs and abnormal encephalogram with less side-effects in comparing with Ritalin (P<0 05). Moreover, YZD could obviously improve the learning memory disturbance induced by scopolamine, sodium nitrite and ethanol, and significantly increased the contents of DA in cerebral tissue, as compared with that of the control group, the difference was significant (P<0 01). It also showed effect on DOPAC, NE, HVA, 5-HT and 5-HIAA of mice in certain degree. Conclusion: YZD is an effective drug in treating CHS, its mechanism might be probably related to the improvement of the memory and the enhancement of DA receptor in cerebral tissue.
Keywords:childhood hyperkinetic syndrome   Yizhidan   Ritalin   clinical therapeutic effect   dysmnesia model   monoamine neurotransmitter
本文献已被 CNKI 维普 万方数据 等数据库收录!
点击此处可从《中国中西医结合杂志》浏览原始摘要信息
点击此处可从《中国中西医结合杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号